Annual Costs of Benign Prostatic Hyperplasia in New Zealand

PharmacoEconomics

Volumn 4, Issue 6, 1993, Pages 455-468

  Scott, W Guy ^a   Scott, Helen M ^a  

^a Intl Ocean Inst Reg Ctr A   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COST OF ILLNESS; ECONOMICS; FEE; HEALTH CARE COST; HUMAN; MALE; MORTALITY; NEW ZEALAND; PROSTATE HYPERTROPHY; QUALITY OF LIFE;

AGED; COST OF ILLNESS; HEALTH CARE COSTS; HUMAN; MALE; MIDDLE AGE; NEW ZEALAND; PRESCRIPTION FEES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SUPPORT, NON-U.S. GOV'T;

EID: 0027876471     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-199304060-00007     Document Type: Article

References (26)

1. Epidemiology and natural history of benign prostatic hyperplasia
2. The epidemiology of BPH
3. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic interventions
4. Incontinence, the secret problem
5. Treatment of BPH
6. Editorial. Proslatic-speciflc antigen. Lancet 2: 318–319, 1988
7. Factors associated with sexual dysfunction following transurethral resection of the prostate
8. Hormonal treatment of BPH
9. Indirect costs in economic studies: confronting the confusion
10. How is BPH diagnosed? How will the guidelines help?